EI
CLBT icon

EAM Investors’s Cellebrite CLBT Stock Holding History

EAM Investors’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-153,109
Closed -$1.17M – 262
2023
Q3 		$1.17M Buy
153,109
+21,159
+16% +$159K 0.23% 205
2023
Q2 		$950K Buy
+131,950
New +$769K 0.18% 242

Other funds holding CLBT

IIGPLP
IGP Investments (G.P.L.P.) Herzliya, Israel $6.25M AUM 18.64% 1-Year Est. Return
TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

EAM Investors's CLBT Position: Q4 2023 in Review

EAM Investors sold out of Cellebrite (CLBT) in Q4 2023, closing a stake of 153,109 shares — an estimated $1.17M sold.

EAM Investors first reported a position in CLBT in Q2 2023 and held it in 2 quarters. The position peaked at $1.17M in Q3 2023. 116 funds tracked by Wall St. Rank hold CLBT as of Q4 2023.

  • EAM Investors reported no remaining Cellebrite position as of Q4 2023 after selling out during the quarter.
  • EAM Investors sold 153,109 Cellebrite shares in Q4 2023, an estimated $1.17M.
  • EAM Investors first reported a position in Cellebrite in Q2 2023 and held it in 2 quarters.
  • EAM Investors's Cellebrite position peaked at $1.17M in Q3 2023.
  • 116 funds tracked by Wall St. Rank held Cellebrite as of Q4 2023.

Based on EAM Investors's 13F filing for Q4 2023, filed 14 Feb 2024.